Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters

Results from a trial of intramuscular interferon β-1a

D. M. Miller, B. Weinstock-Guttman, Dennis Bourdette, X. You, P. Foulds, R. A. Rudick

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: A randomized, placebo-controlled, multicenter study of weekly intramuscular injections of interferon beta-1a (IFNβ-1a) in relapsing-remitting multiple sclerosis included the Sickness Impact Profile (SIP), a validated measure of patient-reported quality of life (QoL).Objective: To demonstrate the impact of moderate to severe SIP disability at baseline and change in QoL as measured by SIP over 2 years in relation to other study parameters.Methods: In 158 patients, SIP scores were determined at baseline and 2 years. Scores were correlated with disease progression and treatment.Results: Patients who experienced disability progression, as defined by Expanded Disability Status Scale (EDSS) and annualized relapse rate, during the study demonstrated significant worsening in Physical SIP scores compared with patients who did not progress (p = 0.031). In patients with low SIP scores, indicating moderate or severe disability at baseline, treatment with IFNβ-1a significantly improved Physical SIP subscores.Conclusions: Patients with disability progression defined using EDSS, the physician-derived primary outcome measure, had Physical SIP scores indicating worsening disability, validating the physician-derived primary outcome measure using patient self-report. Treatment with IFNβ-1a had beneficial effects on QoL in patients with worse SIP scores at baseline.

Original languageEnglish (US)
Pages (from-to)734-742
Number of pages9
JournalMultiple Sclerosis
Volume17
Issue number6
DOIs
StatePublished - 2011

Fingerprint

Sickness Impact Profile
Relapsing-Remitting Multiple Sclerosis
Interferons
Quality of Life
Outcome Assessment (Health Care)
Physicians
Intramuscular Injections
Self Report
Multicenter Studies
Disease Progression
Therapeutics
Placebos

Keywords

  • interferon beta-1a
  • multiple sclerosis
  • quality of life
  • relapsing-remitting multiple sclerosis
  • sickness impact profile

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters : Results from a trial of intramuscular interferon β-1a. / Miller, D. M.; Weinstock-Guttman, B.; Bourdette, Dennis; You, X.; Foulds, P.; Rudick, R. A.

In: Multiple Sclerosis, Vol. 17, No. 6, 2011, p. 734-742.

Research output: Contribution to journalArticle

@article{0879e992a63345edb6bbe5c5a0fac2e1,
title = "Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: Results from a trial of intramuscular interferon β-1a",
abstract = "Background: A randomized, placebo-controlled, multicenter study of weekly intramuscular injections of interferon beta-1a (IFNβ-1a) in relapsing-remitting multiple sclerosis included the Sickness Impact Profile (SIP), a validated measure of patient-reported quality of life (QoL).Objective: To demonstrate the impact of moderate to severe SIP disability at baseline and change in QoL as measured by SIP over 2 years in relation to other study parameters.Methods: In 158 patients, SIP scores were determined at baseline and 2 years. Scores were correlated with disease progression and treatment.Results: Patients who experienced disability progression, as defined by Expanded Disability Status Scale (EDSS) and annualized relapse rate, during the study demonstrated significant worsening in Physical SIP scores compared with patients who did not progress (p = 0.031). In patients with low SIP scores, indicating moderate or severe disability at baseline, treatment with IFNβ-1a significantly improved Physical SIP subscores.Conclusions: Patients with disability progression defined using EDSS, the physician-derived primary outcome measure, had Physical SIP scores indicating worsening disability, validating the physician-derived primary outcome measure using patient self-report. Treatment with IFNβ-1a had beneficial effects on QoL in patients with worse SIP scores at baseline.",
keywords = "interferon beta-1a, multiple sclerosis, quality of life, relapsing-remitting multiple sclerosis, sickness impact profile",
author = "Miller, {D. M.} and B. Weinstock-Guttman and Dennis Bourdette and X. You and P. Foulds and Rudick, {R. A.}",
year = "2011",
doi = "10.1177/1352458510397221",
language = "English (US)",
volume = "17",
pages = "734--742",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters

T2 - Results from a trial of intramuscular interferon β-1a

AU - Miller, D. M.

AU - Weinstock-Guttman, B.

AU - Bourdette, Dennis

AU - You, X.

AU - Foulds, P.

AU - Rudick, R. A.

PY - 2011

Y1 - 2011

N2 - Background: A randomized, placebo-controlled, multicenter study of weekly intramuscular injections of interferon beta-1a (IFNβ-1a) in relapsing-remitting multiple sclerosis included the Sickness Impact Profile (SIP), a validated measure of patient-reported quality of life (QoL).Objective: To demonstrate the impact of moderate to severe SIP disability at baseline and change in QoL as measured by SIP over 2 years in relation to other study parameters.Methods: In 158 patients, SIP scores were determined at baseline and 2 years. Scores were correlated with disease progression and treatment.Results: Patients who experienced disability progression, as defined by Expanded Disability Status Scale (EDSS) and annualized relapse rate, during the study demonstrated significant worsening in Physical SIP scores compared with patients who did not progress (p = 0.031). In patients with low SIP scores, indicating moderate or severe disability at baseline, treatment with IFNβ-1a significantly improved Physical SIP subscores.Conclusions: Patients with disability progression defined using EDSS, the physician-derived primary outcome measure, had Physical SIP scores indicating worsening disability, validating the physician-derived primary outcome measure using patient self-report. Treatment with IFNβ-1a had beneficial effects on QoL in patients with worse SIP scores at baseline.

AB - Background: A randomized, placebo-controlled, multicenter study of weekly intramuscular injections of interferon beta-1a (IFNβ-1a) in relapsing-remitting multiple sclerosis included the Sickness Impact Profile (SIP), a validated measure of patient-reported quality of life (QoL).Objective: To demonstrate the impact of moderate to severe SIP disability at baseline and change in QoL as measured by SIP over 2 years in relation to other study parameters.Methods: In 158 patients, SIP scores were determined at baseline and 2 years. Scores were correlated with disease progression and treatment.Results: Patients who experienced disability progression, as defined by Expanded Disability Status Scale (EDSS) and annualized relapse rate, during the study demonstrated significant worsening in Physical SIP scores compared with patients who did not progress (p = 0.031). In patients with low SIP scores, indicating moderate or severe disability at baseline, treatment with IFNβ-1a significantly improved Physical SIP subscores.Conclusions: Patients with disability progression defined using EDSS, the physician-derived primary outcome measure, had Physical SIP scores indicating worsening disability, validating the physician-derived primary outcome measure using patient self-report. Treatment with IFNβ-1a had beneficial effects on QoL in patients with worse SIP scores at baseline.

KW - interferon beta-1a

KW - multiple sclerosis

KW - quality of life

KW - relapsing-remitting multiple sclerosis

KW - sickness impact profile

UR - http://www.scopus.com/inward/record.url?scp=79959441293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959441293&partnerID=8YFLogxK

U2 - 10.1177/1352458510397221

DO - 10.1177/1352458510397221

M3 - Article

VL - 17

SP - 734

EP - 742

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 6

ER -